Skip to main content

Research summary

Research Hub

GH 191AA (Somatropin)

Clinical10 studies

Somatropin is a recombinant form of human growth hormone composed of 191 amino acids, identical to endogenous pituitary growth hormone and extensively studied in endocrine research.

Being studied for

  • Growth hormone deficiency research
  • IGF-1 signaling pathways
  • Metabolic and body composition studies

Published Research

Evidence profile

Human Phase 3 evidence

10 cited publications · 2 primary trials

Findings below belong to the studies that reported them. They describe the material and conditions those authors used, not this product, and not an outcome to expect.

Supporting evidence

ClinicalPrimary trial · Phase 3

Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study

Deal CL et al. · The Journal of clinical endocrinology and metabolism · 2022

The study reportedThe efficacy of once-weekly somatrogon was noninferior to once-daily somatropin, with similar safety and tolerability profiles. (ClinicalTrials.gov no. NCT02968004).

PMID 35405011DOI 10.1210/clinem/dgac220NCT02968004View on PubMed
ClinicalPrimary trial · Phase 3

Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial

Thornton PS et al. · The Journal of clinical endocrinology and metabolism · 2021

The study reportedThe trial met its primary objective of noninferiority in AHV and further showed superiority of lonapegsomatropin compared to daily somatropin, with similar safety, in treatment-naïve children with GHD.

PMID 34272849DOI 10.1210/clinem/dgab529NCT02781727View on PubMed
ReviewMeta-analysis

Comparison between long-acting pegylated and daily recombinant human growth hormone for pediatric growth hormone deficiency a systematic review

Zhang J et al. · Scientific reports · 2025

The study reportedPEG-rhGH showed superior efficacy to DGH at 12 months and comparable efficacy at other time points. The safety profiles were similar for the two treatments.

PMID 40702077DOI 10.1038/s41598-025-10613-xView on PubMed
ReviewSystematic review

Global trends in recombinant human growth hormone for the treatment of idiopathic short stature: a bibliometric analysis

Ouyang R et al. · Frontiers in medicine · 2025

The study reportedThis bibliometric analysis highlights the progression of rhGH research for ISS, shifting from foundational studies to contemporary priorities such as tailored therapies and clinical outcomes.

PMID 40842547DOI 10.3389/fmed.2025.1577396View on PubMed
ReviewMeta-analysis

Recombinant human growth hormone for children born small for gestational age: meta-analysis confirms the consistent dose-effect relationship on catch-up growth

Crabbé R et al. · Journal of endocrinological investigation · 2008

The study reportedThere is a clear dose-response relationship for r-hGH in the treatment of short children born SGA and the analysis confirmed that treatment with Serono r-hGH formulation 0.033 mg/kg/day should provide a meaningful therapeutic response.

PMID 18475054DOI 10.1007/BF03346369View on PubMed
Additional indexed literature (5)

Published studies summarised here concern the specific investigational or pharmaceutical materials and study conditions described by their authors. Their findings are not performance claims for Cobalt Peptides material. Citations verified against PubMed on 2026-08-09.

Somatropin is a prescription-only medicine in many jurisdictions and is presented here solely in a scientific research context.

Notice

All information on this page is provided strictly for laboratory research and educational purposes only.